Back

Imaging for prevalence assessment of cardiac transthyretin amyloidosis in patients > 60 years hospitalized in cardiology : the IMPACT study

26 August 2023 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: prevalence, genetics, and natural history Imaging ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Elsa Beard

University Hospital of Poitiers, Poitiers (France)

8 More presentations in this session

Presentation thumbnail
Characterization and natural history of phenotypes in hereditary transthyretin amyloidosis
Doctor G. Saturi (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Predictive Value of high-sensitivity cardiac troponin T in patients undergoing 99mTc pyrophosphate scintigraphy for suspected transthyretin amyloid cardiomyopathy
Doctor L. De Michieli (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Prevalence of cardiac amyloidosis in patients undergoing carpal tunnel release with amyloid deposition in removed tenosynovium
Doctor S. Takashio (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
Transtyretin cardiac amyloidosis in the elderly patient: always a wild type?
Doctor J. Costantino (Rome, IT)
Abstract Slides Video
Presentation thumbnail
The clinical significance of transthyretin gene variant homozygosity in variant ATTR-CM
Doctor Y. Razvi (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis: prevalence, genetics, and natural history

The Event

Event poster

ESC Congress 2023

26 August 2023 14:15 CET
You may be interested in
thumbnail
Congress Presentation
True prevalence of transthyretin cardiac amyloidosis in an unselected heart failure with preserved ejection fraction cohort
thumbnail
Congress Presentation
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: final analysis of the TTRACK study
thumbnail
Congress Presentation
Diagnostic yield of scintigraphy in suspected cardiac amyloidosis without left ventricular hypertrophy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources